Mailing Address
45 Rockefeller Plaza, 20th Floor, New York, NY 10111
212-268-1002
Washington DC Office
1101 14th Street NW, Suite 850, Washington, DC 20005
866-399-6262 (Toll Free) | 202-331-2292 (Fax)
Make an online donation today.
Mail your contributions to the address below:
Ovarian Cancer Research Alliance
Post Office Box 32141
New York, NY 10087-2141
Tax ID #13-3806788
We’re here for you! Our Patient Support team is available to take your calls Monday – Friday. Call 212-268-1002 and if no one is available when you call, someone will get back to you within 24 hours.
For all press inquiries, please contact:
Amanita Duga-Carroll
ADC Strategic Communications, Inc.
AI-Powered Platform Launch Sparks Nationwide Conversation The response to OCRA’s launch of the Community Accelerated Research Exchange was immediate and far-reaching. News outlets across the country picked up the story, generating more than 280 media mentions and reaching over 171 million people—a sign of just how much this groundbreaking platform, designed to connect patients, researchers, … Continued
OCRA is proud to announce the launch of the Rare Ovarian Cancer Collaborative Analytics (ROCCA) Platform, an international federated data network funded by OCRA to connect researchers globally and accelerate breakthroughs in rare ovarian cancer research. A collaborative approach to research for rare ovarian cancer ROCCA is launching with two foundational projects: one in mucinous … Continued
We Believe There’s a Better Way to Do Research So we created it. OCRA has launched the most ambitious initiative in our history. We believe it represents a fundamentally new way for research to work—one with the potential to accelerate discovery in gynecologic cancers while serving as a model for breakthroughs across all diseases. We … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
